Cue Biopharma Inc expected to post a loss of 30 cents a share - Earnings Preview

Cue Biopharma

08/08/2023 03:06

* Cue Biopharma Inc  CUE.OQ   CUE.O  is expected to show a
rise in
quarterly revenue when it reports  results on August 9. 
    * The Boston Massachusetts-based  company is expected to
report  a
3,390.4% increase in revenue to $907.5 thousand from $26
thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cue Biopharma Inc
is for
a loss of 30 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cue
Biopharma Inc
is $9​, above​ its last closing price of $3.48. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.32       -0.29      -0.29     Met     0
 Dec. 31 2023  -0.29       -0.31      -0.38     Missed  -22.6
 Sep. 30 2022  -0.38       -0.38      -0.31     Beat    18.4​
 Jun. 30 2022  -0.43       -0.42      -0.37     Beat    12.6
 ​​Mar.        -0.43       -0.43      -0.44     Missed  -2.9
 31 2022                                                
 Dec. 31 2021  -0.45       -0.38      -0.25     Beat    35.1​
 Sep. 30 2021  -0.38       -0.39      -0.41     Missed  -5.1
 Jun. 30 2021  -0.41       -0.42      -0.33     Beat    20.7
 This summary was machine generated August 8 at 02:06 GMT.  All
figures in US dollars  unless otherwise stated